SAN
DIEGO, May 30, 2024 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders,
today announced that the company will participate at two
upcoming investor conferences.
Details of the company's participation are as follows:
- 2024 Jefferies Global Healthcare
Conference
Details: Viking management will deliver a
corporate presentation and participate in 1-on-1 meetings
Conference dates: June 5-6, 2024
Presentation Timing: 10:30 – 10:55
a.m. Eastern on Thursday, June 6,
2024
Location: Marriott Marquis, New
York
- Stifel 2nd European Healthcare
Summit
Details: Viking management will participate in 1-on-1
meetings
Conference Date: June 25-27, 2024
Location: InterContinental Lyon Hotel Dieu, Lyon, France
A live webcast of the Jefferies presentations may be accessed
via a link on the Viking Therapeutics website in the Investors
& Media section under Webcasts. Additionally, a
replay of the webcast will be available on the Viking website
following the conference.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development of novel first-in-class or
best-in-class therapies for the treatment of metabolic and
endocrine disorders, with three compounds currently in clinical
trials. Viking's research and development activities leverage
its expertise in metabolism to develop innovative therapeutics
designed to improve patients' lives. Viking's clinical
programs include VK2809, a novel, orally available, small molecule
selective thyroid hormone receptor beta agonist for the treatment
of lipid and metabolic disorders, which is currently being
evaluated in a Phase 2b study for the treatment of
biopsy-confirmed non-alcoholic steatohepatitis (NASH) and
fibrosis. In a Phase 2a trial for the treatment of
non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C,
patients who received VK2809 demonstrated statistically significant
reductions in LDL-C and liver fat content compared with patients
who received placebo. Viking is also developing VK2735, a
novel dual agonist of the glucagon-like peptide 1 (GLP-1) and
glucose-dependent insulinotropic polypeptide (GIP) receptors for
the potential treatment of various metabolic disorders. Data from a
Phase 1 and a Phase 2 trial evaluating VK2735 (dosed
subcutaneously) for metabolic disorders demonstrated an encouraging
safety and tolerability profile as well as positive signs of
clinical benefit. The company is also evaluating an oral
formulation of VK2735 in a Phase 1 trial. In the rare disease
space, Viking is developing VK0214, a novel, orally available,
small molecule selective thyroid hormone receptor beta agonist for
the potential treatment of X-linked adrenoleukodystrophy
(X-ALD). VK0214 is currently being evaluated in a
Phase 1b clinical trial in patients with the
adrenomyeloneuropathy (AMN) form of X-ALD. Viking holds exclusive
worldwide rights to a portfolio of five therapeutic programs,
including VK2809 and VK0214, which are based on small molecules
licensed from Ligand Pharmaceuticals Incorporated.
For more information about Viking Therapeutics, please
visit www.vikingtherapeutics.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-at-upcoming-investor-conferences-302157125.html
SOURCE Viking Therapeutics, Inc.